Use In Vivo’s exclusive interviews, analysis and critical insights from key players in biopharma, medtech and diagnostics to inform your decision-making
Life science decision makers need a high-level perspective on evolving trends — insight with lasting value that can be revisited as developments unfold. In Vivo delivers the strategic depth that leaders rely on to plan their next move.
In-person fireside chats, weekly podcast episodes, and deep-dive interviews with senior executives and experts across biopharma, medtech and diagnostics.
Strategic deep dives, executive outlooks and thematic series on AI, innovation, precision medicine and the forces shaping the decade ahead.
Norstella's clinical trials, drug pipelines and market metrics databases embedded in original reporting to reveal hidden patterns.
In Vivo has access to top-tier executives across biopharma and medtech who speak candidly about challenges, strategy and the decisions shaping their organizations — and the industry.
In Vivo helps leaders prepare for what’s next — not just respond to what’s happening now. Ongoing series and thematic coverage tackle the biggest strategic questions facing life sciences leadership.
In Vivo taps into Norstella’s extensive databases on clinical trials, drug pipelines and market metrics to uncover trends and validate editorial insights — combining quantitative depth with expert analysis.
In Vivo’s weekly video podcast series goes beyond the soundbite — giving listeners nuanced, strategic perspectives on the decisions and trends shaping biopharma and medtech from the executives living them.
Scrip’s Jessica Merrill talks about how mid-cap biopharma leaders are finding ways to outmaneuver their largest commercial competitors and the strategies driving their growth.
Annexon CEO Doug Love discusses commercializing Ixoberogene in two distinct market settings simultaneously.
ElevateBio's CSO Amy Pooler on why no single gene editing modality will dominate, and how AI-designed enzymes and smarter delivery tools will shape the field.
Deals, pipelines and late-stage bets — the strategic moves behind the companies driving growth.
How AI, digital health, precision medicine and emerging technologies are changing drug discovery, development and the competitive landscape.
In-depth interviews with CEOs and C-suite leaders on the decisions, challenges and opportunities shaping their world.
How reimbursement, health economics and policy shifts connect to commercial and R&D strategy for life sciences leaders.
Original data-driven analysis powered by Norstella databases, surfacing trends in pipelines, deals and market performance.
In Vivo's flagship weekly podcast series featuring candid conversations with senior leaders on strategy, disruption and what's coming next.
In Vivo’s thematic series and annual Outlook issue give leaders a forward-looking view of the forces reshaping biopharma, medtech and diagnostics — so strategy can be built around where the industry is going, not just where it has been.
In Vivo’s exclusive C-suite interviews go beyond PR messaging to reveal the strategic thinking, competitive concerns and investment priorities of the executives who drive the life sciences sector — revealing context that is unavailable anywhere else.
In Vivo’s coverage of growth, deals and market intelligence — backed by Norstella data — surfaces patterns in AI-driven biotech financing, pipeline acquisitions and late-stage partnering that give BD&L and corporate strategy teams an earlier read on market direction.
Decades of archived reporting give strategy and portfolio teams the historical context to assess how current decisions compare to what has worked — and what hasn’t — across biopharma and medtech over time.
From biopharma boardrooms to medtech strategy teams, In Vivo serves senior leaders who need intelligence with depth — not just the daily news cycle.
CEOs and senior strategy experts use In Vivo to understand how competitors are positioning, what's driving deals and where the market is heading.
Chief scientific officers and heads of R&D use In Vivo's deep-dive analysis on AI, precision medicine and technology trends to inform scientific and portfolio strategy.
Leaders across medical devices and diagnostics use In Vivo to track innovation trends, competitive moves and the strategic implications of regulatory and market shifts.
Investors use In Vivo's deal analysis, executive interviews and market intelligence to inform investment thesis development and portfolio strategy.
Strategy and business development teams use In Vivo to identify deal patterns, benchmark against peers and understand the strategic rationale behind major industry moves.
Strategy consultants and life sciences advisors cite In Vivo's exclusive interviews and data-driven analysis in client work requiring authoritative sector intelligence.
Citeline’s award-winning publications provide in-depth coverage of the pharmaceutical industry, thanks to 40+ in-house journalists, located around the world, who tackle the tough issues with precision, persistence and passion.
In Vivo provides comprehensive industry analysis across areas ranging from pharmaceutical regulation and policy to generics and the medtech industry, with sector specialists bringing decades of combined experience.
Norstella’s analysts are trusted advisors to a broad spectrum of the industry, including biopharma, biotech, financial and professional services, CDMOs and CROs — with Norstella data and analyst insights regularly embedded in In Vivo content.
In Vivo is Norstella’s strategic intelligence publication for senior life sciences decision makers. It delivers expert analysis, exclusive C-suite interviews and data-driven reporting on R&D, business development and innovation across biopharma, medtech and diagnostics.
Scrip focuses on day-to-day commercial intelligence for biopharma teams — pipelines, deals and market moves. In Vivo operates at a higher strategic altitude, focusing on the forces and decisions shaping the life sciences sector over the longer term, with deep executive access and thematic analysis.
Strategic Intent is In Vivo’s weekly podcast, featuring candid conversations with senior executives across biopharma and medtech on the strategy, challenges and opportunities shaping their organizations and the broader industry.
Outlook is In Vivo’s award-winning, annual preview issue — a forward-looking reference for life sciences leaders covering the key themes, market dynamics and strategic questions expected to define the year ahead.
In Vivo taps into Norstella’s extensive databases on clinical trials, drug pipelines and market metrics to produce original, data-driven reports and validate editorial insights. Complex data is presented in clear, actionable formats integrated directly into editorial content.
A specialist is ready to support your request. Tell us what you're looking for and our team will be in touch shortly.
